Skip to content

Next-generation Sequencing (NGS) of Peripheral Blood Immune Repertoire in Graves' Disease

Next-generation Sequencing (NGS) of Peripheral Blood Immune Repertoire in Graves' Disease

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02210741
Enrollment
200
Registered
2014-08-07
Start date
2014-08-31
Completion date
2024-02-29
Last updated
2014-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Graves Disease

Keywords

immune repertoire, Graves' disease

Brief summary

Graves' disease (MIM 27500) is the leading cause of hyperthyroidism worldwide. The prevalence of Graves' disease is quite high (2.7% in women), and there is solid evidence of genetic predisposition. Despite its clinical and scientific significance, Graves' disease is still mysterious in terms of its susceptibility genes or pathophysiological mechanisms. The immune repertoire, being the sum of T and B lymphocytes in a body at any given time, is both a snapshot and a historical record of a person's immune function. Thanks to the power of next-generation sequencing (NGS), massively parallel sequencing of the B cell and T cell receptors suddenly becomes plausible, and opens a door for many creative approaches to study immune related diseases. The ultimate goal of this project is to use both the NGS deep sequencing and immune repertoire experiment to perform Graves' disease sub-group genetic fine mapping, and to identify Graves' disease-specific T cell and B cell receptors. Furthermore, using the immune repertoire approach, investigators want to study the critical epitopes of thyroid auto-antigens, and to delineate the pathophysiological steps in various disease stages and in various sub-groups. Investigators expect to solve the immune repertoire of Graves' disease of different sub-group presentations and at various disease activity stages.

Interventions

None listed

Sponsors

National Taiwan University Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Patients with Graves disease

Design outcomes

Primary

MeasureTime frameDescription
B lymphocyte and T lymphocyte receptor profiles of Graves' disease patientsThree yearsB lymphocyte and T lymphocyte receptor profiles mean the sequence of the receptors and also the quantity of the lymphocytes with those specific receptor sequences.

Countries

Taiwan

Contacts

Primary ContactPei-Lung Chen
paylong@gmail.com886-2-23123456

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026